
CLAIMS

WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of compound 1:




1,

or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in the manufacture of a medicament for the treatment of a fungal infection in a subject;

wherein,

the fungal infection in the subject is caused by *Candida* spp., *Aspergillus* spp., *Scedosporium* spp., *Fusarium* spp., *Paecilomyces* spp., *Purpureocillium* spp., *Dematiaceous* spp., *Rhizopus*, *Mucor* spp., *Lichtheimia* spp., *Cunninghamella* spp., *Acremonium* spp., *Rasamsonia* spp., *Scedosporium* spp., *Schizophyllum* spp., *Trichoderma* spp., *Alternaria* spp., *Cladophialophora* spp., *Cladosporium* spp., *Exophiala* spp., *Fonsecaea* spp., *Lomentospora* spp., *Phialophora* spp., *Scopulariopsis* spp., *Magnusiomyces* (*Geotrichum)* spp., *Trichosporon* spp., *Malassezia* spp., *Saprochaete* spp., *Kodamaea* spp., *Rhodotorula* spp., *Saccharomyces* spp., *Pseudozyma* spp., *Sporobolomyces* spp., *Exophiala* spp., *Lacazia* spp., *Emmonsia* spp., *Wickerhamomyces (Pichia)* spp., *Emergomyces* spp., *Talaromyces* spp., or Emmonsia-like fungi, or a combination thereof;

the therapeutically effective amount of compound 1 provides a steady state 24-hr Area Under the Concentration-Time Curve ($AUC_{0\text{-}24}$) in the subject of at least about 100 µg×hr/mL of compound 1A:



1A;

wherein the subject has a contradiction to standard of care antifungal therapy; and

wherein the treatment comprises

daily administration of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for at least 1-4 weeks.

2. The use of claim 1, wherein the contradiction to standard of care antifungal therapy is due to reduced kidney function.

3. The use of claim 1 or claim 2, wherein the contradiction to standard of care antifungal therapy is due to a kidney disease in the subject.


4. The use of claim 3, wherein the kidney disease is chronic kidney disease, metabolic syndrome, vesicoureteral reflux, tubulointerstitial renal fibrosis, IgA nephropathy, diabetic nephropathy, Alport syndrome, HIV associated nephropathy, glomerular nephritis (GN), focal segmental glomerulosclerosis, membranous glomerulonephritis, mesangiocapillary GN, interstitial fibrosis and tubular atrophy (IFTA), acute kidney injury (AKI), acute obstructive nephropathy, or drug induced fibrosis.

5. The use of claim 3, wherein the kidney disease is chronic kidney disease (CKD).

6. The use of claim 5, wherein chronic kidney disease (CKD) is Stage 1 CKD, Stage 2 CKD, Stage 3 CKD, Stage 4 CKD, or Stage 5 CKD.

7. The use of claim 2, wherein the subject has high levels of protein in his or her urine (proteinuria).


8. Use of a therapeutically effective amount of compound 1:



1,

or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in the manufacture of a medicament for the treatment of a fungal infection in a subject;

wherein, the therapeutically effective amount of compound 1 provides a steady state 24-hr Area Under the Concentration-Time Curve (AUC_{0-24}) in the subject of at least about 100 µg×hr/mL of compound 1A:



1A;

wherein the treatment comprises daily administration of compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for at least 1-4 weeks;

wherein a dose adjustment of the compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof that is to be administered to the subject is not required based on the kidney status of the subject.